Recommendation of the President – Ferriprox (deferiprone)
On 6 September 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 90/2024 on the appropriateness of granting reimbursement approval for Ferriprox (deferiprone) for the indication: neurodegeneration with iron deposition in the brain